CD304 (BDCA-4) Antibody, anti-human, REAfinity™
Synonyms: NRP1, BDCA-4, NP1, Nrp, VEGF165R, Neuropilin-1
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
10 Citations3 Images
Clone:
REA774 | AD5-17F6
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD304 (BDCA-4) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 615
PE-Vio 770
Vio Bright B515
Vio Bright R720
Vio Bright V423
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-112-046, 130-111-894
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with CD304 (BDCA-4) antibodies or with the corresponding REA Control (S) antibodies (left image) as well as with CD123 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-111-894, 130-112-046
Testing grade:
Mass cytometry applications
pure
Conjugate:
pure
Used products:
130-124-318
Extended validation for CD304 (BDCA-4) Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA774
AD5-17F6
high
446921
high
U21-1283
high
12C2
high
REAL222
high

Cells were incubated with an excess of purified unconjugated CD304 (BDCA-4) (REA774) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD304 (BDCA-4) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD304 (BDCA-4)-PE (REA774, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD304 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD304-PE, clone (REA774). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD304 (BDCA-4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD304 (BDCA-4) antibodies and with a suitable counterstaining. As a control, CD304 (BDCA-4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD304 (BDCA-4) (REA774). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD304 (BDCA-4) Antibody, anti-human, REAfinity™
Overview

Clone REA774 recognizes the human CD304 (BDCA-4) antigen. Like CD303 (BDCA-2), the CD304 (BDCA-4) antigen is specifically expressed on human plasmacytoid dendritic cells in blood and bone marrow. Unlike CD303 (BDCA-2), expression of CD304 (BDCA-4) is up-regulated on plasmacytoid dendritic cells and induced on myeloid cells upon culturing. In inflamed tonsils, CD304 expression, apart from plasmacytoid dendritic cells, is also detected primarily on follicular B helper memory T cells. The CD304 (BDCA-4) is identical to neuropilin-1 (NP-1), a neuronal receptor, which is known to be expressed on numerous nonhematopoietic cell types, including neurons, endothelial, and tumor cells. CD1a+ dendritic cells generated ex vivo from monocytes or hematopoietic precursor cells are CD304+ but CD303 (BDCA-2)–.

Additional information: Clone REA774 displays negligible binding to Fc receptors.

Alternative names

NRP1, BDCA-4, NP1, Nrp, VEGF165R, Neuropilin-1

Detailed product information

Technical specifications

Clone
REA774
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD304 (BDCA-4)
Molecular mass of antigen [kDa]
101
Distribution of antigen
dendritic cells, endothelial cells, neurons, T cells, CNS cells, heart, kidney, liver, placenta
Entrez Gene ID
RRID
AB_2928396, AB_2928395, AB_2921799, AB_2921793, AB_2657208, AB_2657216, AB_2657215, AB_2928393, AB_2928394, AB_2657210, AB_2657209, AB_2657217, AB_2889545, AB_2657212, AB_2657213, AB_2657220, AB_2657211, AB_2657218, AB_2657207, AB_2657214, AB_2657219

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD304 (BDCA-4) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?